NCT00407563

Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer

A Phase 2 Study of Bevacizumab With Abraxane in Patients With Recurrent, Platinum-Resistant Primary Epithelial Ovarian or Primary Peritoneal Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Accelerated Community Oncology Research Network · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer. The study will also evaluate how the patient's quality of life is during their treatment.

Conditions

• Epithelial Ovarian Cancer
• Primary Peritoneal Carcinoma

Interventions

Type	Name	Description
DRUG	Bevacizumab	Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle.
DRUG	Abraxane	Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.

Timeline

• Start date: 2007-01-01
• Primary completion: 2011-02-01
• Completion: 2011-02-01
• First posted: 2006-12-05
• Last updated: 2012-04-05
• Results posted: 2012-04-05

Locations

11 sites across 1 country: United States